12:33:59 EDT Sun 16 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:OTLK - OUTLOOK THERAPEUTICS INC - https://outlooktherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
OTLK - Q0.16.20·7.940.77.67+0.010.1113.27731,3557.67  7.96  7.5737.20  4.00419:45:01Jun 1115 min RT 2¢

Recent Trades - Last 10 of 1355
Time ETExPriceChangeVolume
19:45:01Q7.54-0.123
16:05:06Q7.670.011,000
16:02:00Q7.670.0119
16:00:06Q7.670.011
16:00:00Q7.670.01424
16:00:00Q7.670.01809
16:00:00Q7.670.0134
16:00:00Q7.670.016
16:00:00Q7.670.0141
16:00:00Q7.670.01303

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-11 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at the Virtual Investor Pitch Conference
2024-05-28 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Receives European Commission Marketing Authorization for LYTENAVA(TM) (bevacizumab gamma) for the Treatment of Wet AMD
2024-05-15 17:00U:OTLKNews ReleaseOutlook Therapeutics(TM) Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
2024-05-13 08:50U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
2024-05-09 08:45U:OTLKNews ReleaseOutlook Therapeutics(TM) to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
2024-05-02 09:05U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at the Retina World Congress 2024
2024-04-29 09:00U:OTLKNews ReleaseOutlook Therapeutics(TM) to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
2024-04-15 16:15U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Closing of Private Placement of $5.0 Million
2024-03-22 07:36U:OTLKNews ReleaseOutlook Therapeutics(TM) Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
2024-03-18 17:10U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Closing of Private Placement of up to $159 Million
2024-03-12 08:05U:OTLKNews ReleaseOutlook Therapeutics(TM) Announces Effective Date for 1-for-20 Reverse Stock Split
2024-02-14 08:05U:OTLKNews ReleaseOutlook Therapeutics ‚ ® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
2024-01-31 08:05U:OTLKNews ReleaseOutlook Therapeutics ‚ ® Doses First Subject in NORSE EIGHT
2024-01-23 08:00U:OTLKNews ReleaseOutlook Therapeutics ‚ ® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
2024-01-01 17:04U:OTLKNews ReleaseOTLK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
2023-12-31 12:04U:OTLKNews ReleaseOTLK IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
2023-12-30 09:08U:OTLKNews ReleaseOTLK DEADLINE ALERT: ROSEN, A LEADING AND RANKED FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
2023-12-29 20:35U:OTLKNews ReleaseOTLK DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
2023-12-28 16:03U:OTLKNews ReleaseOTLK DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
2023-12-25 14:34U:OTLKNews ReleaseROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK